Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant OCD
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01043900 |
Recruitment Status :
Completed
First Posted : January 7, 2010
Last Update Posted : January 7, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
OCD is a chronic condition with a high rate of poor responders to conventional treatments, such as antidepressants and psychotherapy. Chronic symptoms can lead to important social impairment and suffering for patients and families.
The present study aims to investigate if the addition of transcranial magnetic stimulation can provide enhanced response to conventional treatment.
Transcranial magnetic stimulation is a noninvasive technique that can influence specific areas of the brain and has very few side effects.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obsessive-Compulsive Disorder | Procedure: repetitive transcranial magnetic stimulation (rTMS) | Phase 2 |
The treatment with transcranial magnetic stimulation requires attendance to hospital daily sessions for 6 consecutive weeks. Each session lasts up to 30 minutes.
Side effects include scalp discomfort and mild headache. No anesthesia is required.
Stimulation aims the dorsolateral prefrontal cortex, a region previously studied to treat depression symptoms with positive results. The present technique has never been employed in previous studies, but risks are insignificant
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Right Prefrontal High Frequency rTMS in Treatment of Resistant OCD: a Double Blind, Randomized Controlled Trial |
Study Start Date : | August 2003 |
Actual Primary Completion Date : | August 2009 |
Actual Study Completion Date : | August 2009 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Sham rTMS
Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
|
Procedure: repetitive transcranial magnetic stimulation (rTMS)
30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
Other Name: TMS |
Active Comparator: Active rTMS
Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
|
Procedure: repetitive transcranial magnetic stimulation (rTMS)
30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
Other Name: TMS |
- A reduction of at least 30 % in the Yale-Brown Obsessive Compulsive Scale (YBOCS) scores and an "improved" or "much improved" score on the Clinical Global Impression (CGI) improvement scale by the end of follow-up [ Time Frame: 3 - 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- resistant OCD patients: maximum 25% reduction in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores after at least 3 adequate trials with serotonin reuptake inhibitors (SRI) (including clomipramine) and 20 hours of cognitive behavioral therapy (CBT) or documented intolerance to either treatment.
Exclusion Criteria:
- metallic cerebral implants
- history of severe trauma or brain injury
- organic brain disease
- severe somatic disease
- history of drug dependence
- chronic psychosis
- present manic state

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01043900
Principal Investigator: | Carlos G Mansur, MD | Department and Institute of Psychiatry, General Hospital, University of São Paulo Medical School |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Carlos Gustavo Mansur, Department and Institute of Psychiatry, General Hospital, University of São Paulo Medical School |
ClinicalTrials.gov Identifier: | NCT01043900 History of Changes |
Other Study ID Numbers: |
cgmansur01 |
First Posted: | January 7, 2010 Key Record Dates |
Last Update Posted: | January 7, 2010 |
Last Verified: | September 2009 |
Keywords provided by University of Sao Paulo General Hospital:
Obsessive-Compulsive Disorder rTMS Transcranial Magnetic Stimulation treatment randomized controlled trials |
Additional relevant MeSH terms:
Compulsive Personality Disorder Obsessive-Compulsive Disorder Personality Disorders Mental Disorders Anxiety Disorders |